# Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System

> **NCT00698425** · PHASE1 · COMPLETED · sponsor: **Eyegate Pharmaceuticals, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Healthy

## Interventions

- **OTHER:** EyeGate II® Drug Delivery System
- **DRUG:** Citrate buffer

## Key facts

- **NCT ID:** NCT00698425
- **Lead sponsor:** Eyegate Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2010-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698425, "Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00698425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*